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ABSTRACT
In colorectal cancer (CRC), RHAMM is an independent adverse prognostic factor. 
The aim of the study was therefore to investigate on the role of RHAMM as a potential 
direct driver of cell proliferation and migration in CRC cell lines and to identify 
pathways dependent on RHAMM in human CRC.
Proliferation, cell cycle alterations and invasive capacity were tested in two 
RHAMM- and control- knockdown CRC cell lines by flow cytometry and in vitro assays. 
Tumorigenicity and metastasis formation was assessed in immunodeficient mice. RNA-
Seq and immunohistochemistry was performed on six RHAMM+/- primary CRC tumors.
In vitro, silencing of RHAMM inhibited CRC cell migration and invasion by 50% 
(p<0.01). In vivo, RHAMM knockdown resulted in slower growth, lower tumor size 
(p<0.001) and inhibition of metastasis (p<0.001). Patients with RHAMM-high CRC 
had a worse prognosis (p=0.040) and upregulated pathways for cell cycle progression 
and adhesion turnover.
RHAMM overexpression is correlated with increased migration and invasion of 
CRC cells, leads to larger, fast growing tumors, and its downregulation essentially 
abolishes metastasis in mouse models. RHAMM is therefore a promising therapeutic 
target in all CRC stages as its inhibition affects growth and dissemination of the 
primary CRC as well as the metastases.
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INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes 
of cancer-related deaths in western countries. Over a third 
of the patients diagnosed with CRC will die within 5 
years, mostly from widespread metastatic disease [1, 2]. 
Targeted therapy approaches are currently only being used 
to treat patients with metastatic CRC, outlining the need to 
identify additional therapeutic targets which may help to 
prevent tumor dissemination.
RHAMM (Receptor for Hyaluronic Acid Mediated 
Motility/HMMR/CD168) was first characterized as a 
protein involved in cell locomotion. Today, RHAMM 
is known to be a versatile protein, typically activated in 
wound healing [3], and found on the cell surface, in the 
cytoplasm, and in the nucleus of many different cell types 
[4]. In response to hyaluronic acid (HA), TGF-β or PDGF 
[5], RHAMM can activate various signaling cascades. For 
instance, by binding to proteins such as ERK1/2 [6, 7], 
FAK [8], or Src [9], RHAMM was reported to activate 
the respective pathways. Additionally, RHAMM can target 
MEK1 and ERK1/2 to the cytoskeleton and nucleus, thus 
regulating mitotic spindle integrity, cell cycle progression, 
and expression of genes governing reorganization and 
degradation of the extracellular matrix (ECM). It is 
functionally linked to key centrosomal proteins such as 
the Aurora kinase A [10–12], and is essential for bipolar 
spindle formation and cell division fidelity [13, 14].
Overexpression of RHAMM has been linked 
to disease progression in many solid [15, 16] and 
haematological cancers [17]. We have previously 
described RHAMM as an independent adverse prognostic 
factor in mismatch repair (MMR) proficient tumors in 
a cohort of 1420 CRC patients [18]. Further analyses 
confirmed that the prognostic impact of RHAMM ranked 
above other established prognostic factors, such as tumor 
grade and vascular invasion [19]. Additionally, in a recent 
study, we have analyzed RHAMM expression in highly 
aggressive tumor cells, termed tumor buds [20]. These are 
defined as clusters of up to 4 cells at the invasive front and 
thought to be detached, motile tumor cells in the process 
of epithelial-mesenchymal-like transition and metastatic 
dissemination. A high number of buds at the invasion front 
is one the strongest adverse prognostic factor in CRC [21]. 
We speculated that RHAMM overexpression on tumor 
buds would increase motility, invasion into lymph and 
blood vessels and dissemination, thus contributing to 
an adverse outcome. Indeed, the presence of RHAMM-
positive tumor buds correlated strongly with aggressive 
clinicopathological features and added significant 
prognostic information to the tumor-node-metastasis 
(TNM) classification [20].
Therefore, based on our previous studies, and the 
literature describing the many key processes this protein 
is involved in, RHAMM can be described as a very 
promising prognostic factor and a potential therapeutic 
target in CRC. Previous molecular signaling pathway 
studies indicate that RHAMM could be a direct driver of 
cell proliferation and migration, which might contribute 
to early metastatic dissemination, which has, to our 
knowledge, never been tested in CRC. In the present study, 
we analyzed the effect of RHAMM expression on the 
proliferation, cell cycle, migration and invasive potential 
of CRC cell lines and the growth and tumorigenicity of 
CRC tumors in vivo. We additionally use RNA sequencing 
to identify specific transcripts and pathways which are 
characteristic for patients with RHAMM positive or 
negative CRC tumors.
RESULTS
Patient survival is correlated to RHAMM 
expression in tumor cells
First, we re-tested the ability of RHAMM expression 
to predict survival in a new, well characterized colorectal 
cancer cohort. Patients with RHAMM high tumors had a 
significantly lower survival rate (p=0.040, HR 1.50, 95% 
CI 1.02-2.21, Supplementary Figure 1).
Subcellular distribution of RHAMM in CRC cell 
lines
RHAMM levels in a panel of eight established 
human CRC cell lines (LoVo, DLD-1, HCT116, HCT15, 
SW620, SW480, HT29, and CACO-2, Supplementary 
Figure 2A,) were analyzed by flow cytometry. High levels 
of cytoplasmic RHAMM were detected in all tested cell 
lines (Supplementary Figure 2B).
Based on our previous studies, we selected a MMR 
proficient (MMR+, HT29) and a deficient (MMR-, 
HCT116) cell line for subsequent functional assays. To 
test for cell surface localization of RHAMM, we labeled 
both cell lines with an anti-RHAMM antibody. While 
the levels of intracellular RHAMM were fairly constant, 
surface RHAMM expression was transient after plating, 
and could be detected on a small fraction of cells 48 
hours after plating, at 50% confluency (data not shown). 
We confirmed previous reports that RHAMM surface 
expression could be induced and increased up to fourfold 
under the same culture conditions by the addition of 
100 μg/ml of its extracellular matrix ligand, HA, to the 
medium (single experiment, Supplementary Figure 3).
Inhibition of RHAMM slows proliferation and 
impacts cell cycle progression of HT29 and 
HCT116 cells in vitro
As levels of RHAMM were high all in CRC cells, 
we did not additionally test RHAMM overexpression. 
HT29 and HCT116, which were stably transduced with 
lentiviral particles carrying either a RHAMM shRNA 
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(RHAMM-) or a scrambled control (RHAMM+, 
Supplementary Figure 4) were analyzed by CYQUANT 
cell proliferation assay and flow cytometry for differences 
in the proliferation rate and cell cycle. RHAMM silencing 
had a mild, but statistically significant effect on the cell 
line’s growth, reducing the proliferation of HT29 and 
HCT116 cells and simultaneously lowering the percentage 
of cells in the S phase (Figure 1).
Inhibition of RHAMM decreases motility and 
invasiveness of HT29 and HCT116 cells in vitro
To test the effect of RHAMM on cell motility, 
the migration of RHAMM- and RHAMM+ HT29 and 
HCT116 cells was tested in a transwell assay. The amount 
of cells that migrated through both uncoated membranes 
and those coated with a Matrigel extracellular matrix was 
Figure 1: RHAMM silencing reduces the rate of proliferation of tumor cells. (A) RHAMM+ and RHAMM- HT29 and 
HCT116 were seeded in a 96-well plate and the proliferation was analyzed every 24 hours for 6 days. The data is plotted as mean +/- 
standard deviation (SD). (B, C) RHAMM silencing reduces the occupancy of the S and G2/M phase of the cell cycle. HT29 and HCT116 
cells were fixed, stained with PI/RNase staining buffer (BD), and analyzed on the BD LSRFortessa. The data are an average of three 
independent experiments.
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significantly higher in RHAMM+ than in RHAMM- cells 
(50% increase on average, p<0.01, Figure 2).
RHAMM positive tumors are more tumorigenic 
in vivo
RHAMM- and RHAMM+ HT29 and HCT116 cells 
were injected subcutaneously into immunodeficient NSG 
mice. Tumor growth was followed for up to 5 weeks. 
Already at three (HT29) or four (HCT116) weeks post-
injection, a significant difference in tumor sizes could be 
seen. The final average size of RHAMM+ tumors was 
twofold higher than the RHAMM- tumors (Figure 3, 7500 
mm3 versus 2800 mm3, respectively for HT29 p<0.01, and 
6200 mm3 versus 3100 mm3, respectively for HCT116 
tumors p<0.001).
To test the effect of RHAMM silencing on the 
metastatic potential of colon cancer cells, we intravenously 
injected RHAMM- and RHAMM+ HT29 and HCT116 
cells into NSG mice. After 4 weeks, 8/8 mice injected with 
HCT116 and 4/5 mice injected with HT29 RHAMM+ cells 
developed multiple macroscopically detectable metastases 
in several organs, including liver, lung and kidney. Mice 
injected with RHAMM+ cells developed lymph node 
metastases in 5/8 (HCT116) and 4/5 cases (HT29) (Figure 
4A, 4B). The metastatic nature of macroscopically 
detectable lesions was confirmed by histological evaluation 
(Figure 4B). Mice injected with RHAMM- HT29 cells did 
not develop any metastases (0/5), whereas only one mouse 
injected with RHAMM- HCT116 developed a metastasis 
(lung). Furthermore, after 4 weeks, EpCAM positive 
circulating tumor cells were found almost exclusively in 
mice injected with RHAMM+ cells (Figure 4C).
RHAMM-positive CRC tumors express genes 
correlated with increased cell-cell and cell-
surface detachment, motility and proliferation
RNA-Seq was performed on samples from stage-
matched primary RHAMM high (n=3) and RHAMM 
low (n=3) CRC samples as determined by IHC. Proteins 
in pathways permitting cell cycle progression were 
upregulated in RHAMM high as compared with RHAMM 
low tumors. Conversely, we detected a downregulation 
in the expression of mRNAs coding for factors that 
regulate focal adhesion turnover, cell-substrate and cell-
Figure 2: RHAMM silencing reduces the ability of CRC cells to migrate and invade in vitro. Migration and invasion of 
HT29 (A, C) and HCT116 (B, D) tumor cells. The cells were seeded in the upper chambers of transwell plates onto uncoated (A, B) or 
Matrigel-coated (C, D) membranes (8 μm pores, Corning). At T=20 hours, the number of cells that had migrated into the lower chambers 
were quantified by CyQUANT Cell Proliferation Assay Kit® (Invitrogen). *p≤0.05, **p≤0.01, Students’ t-test (average from 3 independent 
experiments). The data is shown as mean +/- SD.
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cell adhesion in RHAMM high tumors. These and other 
significantly altered pathways (Figure 5) and genes 
(Supplementary data) of interest are shown.
Increased proliferation of RHAMM high tumors 
which were selected for RNA-Seq was confirmed with 
Ki-67 immunohistological staining. All 3 RHAMM high 
tumors expressed Ki-67 in over 75% of the tumor cells, 
whereas the RHAMM low tumors showed an average 
of 40% of Ki-67 expression Interestingly, RHAMM 
low tumors also show lower levels of cleaved Casp3 
(Supplementary Figure 5).
RHAMM expression in matched primary, lymph 
node and distant metastasis
The correlation of RHAMM expression with tumor 
cell spreading was evaluated on 7 matched samples from 
primary tumors, lymph node and liver metastasis. Notably, 
Figure 3: RHAMM silencing reduces the tumorigenicity of CRC cells in vivo. Immunodeficient NGS mice (n=4 per group) 
were injected subcutaneously with 105 control or RHAMM- HT29 or HCT116 cell. (A, B) Growth kinetics of control and RHAMM- HT29 
and HCT116 cells are shown. The data is and plotted as mean +/- SD. (C, D) Final tumor volume of HT29 and HCT116 tumors, with or 
without RHAMM expression, 5 weeks after injection. Data from three separate experiments were pooled. **p≤0.01, ***p≤0.001, Students’ 
t-test. (E, F) HT29 and HCT116 tumors.
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Figure 4: RHAMM silencing suppresses the formation of metastases upon intravenous injection of HCT116 or HT29 
cells. (A) Incidence and location of metastases at the 4 week endpoint. (B) Tissues (lung, liver, kidney and lymph nodes) and corresponding 
hematoxylin and eosin stains of representative metastases induced by HCT116 wild type cells. (C) Number of circulating tumor cells (CTC) 
detected by EpCAM positivity normalized to milliliter of peripheral blood.
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the percentage of RHAMM positive cells increased from 
primary tumors (mean 17%) to liver metastases (mean 
37%, p=0.045, Figure 6), with the lymph node expression 
falling in between.
DISCUSSION
In previous studies, we identified RHAMM 
overexpression as a marker of an aggressive phenotype 
and unfavorable clinical outcome in CRC [18–20]. 
However, whether RHAMM expression is a direct cause 
of tumor spreading remained unclear. Here, to test direct 
causation, we analyzed the effect of RHAMM knockdown 
on cell cycle, proliferation, migration, the invasion 
potential and tumorigenicity of CRC cells in vitro and in 
vivo. Moreover, to try and better understand the underlying 
causes of RHAMM effects on tumor cell behavior in 
CRC, we also evaluate the differences in various cellular 
pathways by testing genes expression in primary tumors 
discordant for RHAMM by RNA-Seq [22].
We originally described RHAMM as a potential 
prognostic factor in colorectal cancer patients [19]. In the 
Figure 5: Pathway changes in RHAMM low versus RHAMM high human CRC samples. Each dot represents one transcript, 
and values are shown as log2 fold changes. In RHAMM low tumors, mRNA coding for factors regulating cell-cell and cell-substrate 
binding are upregulated (yellow and red). In RHAMM high tumors, pathways involved in the cell cycle are upregulated (blue). P-value is 
expressed as dot size: the larger the dot, the more significant the P-value for differential expression between the two groups, adjusted for 
multiple testing.
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present study we can confirm on a new, well characterized 
cohort, that patients with RHAMM high CRC tumors have 
a shorter survival time.
To select an appropriate cellular system, we 
measured RHAMM levels in 8 different, commonly used 
CRC cell lines. All showed high and comparable levels of 
intracellular RHAMM, and cell surface expression could 
additionally be induced by incubation with hyaluronic acid 
(HA), as previously described for other cell types [5, 6, 
23]. We selected representative MMR positive (MMR+) 
HT29 and negative (MMR-) HCT116 cell lines for further 
assays. Interestingly, in vitro, both MMR+ and MMR- 
RHAMM- cells were less motile, had lower invasive 
capabilities, and displayed reduced proliferation rates and 
occupancy of S and G2/M cell cycle phases.
Notably, effects of RHAMM silencing on 
proliferation and cell cycle were only detectable in the 
presence of HA (data without HA not shown). As the 
interaction partner of RHAMM in the ECM, HA is present 
in different forms in quiescent and in inflamed tissues, 
including the tumor stroma, where it is degraded by 
reactive oxygen species and secreted enzymes to a much 
smaller, pro-inflammatory low molecular weight oligomer 
(LMWHA [3]). This degraded molecule can be bound to 
alternate combinations of receptors, and elicits different 
downstream responses within a cell [3]. Therefore, 
in the future it would be advantageous to establish a 
3D co-culture setting to test the effect of RHAMM 
downregulation in the presence of HA of varying sizes.
RHAMM deficient cells were significantly less 
tumorigenic in vivo. Subcutaneous tumor formation was 
more rapid in mice injected with RHAMM+ compared 
with RHAMM- cells. The tumors likewise reached a 
much larger overall size. Unfortunately, this subcutaneous 
tumor model of CRC yields compact tumors with a largely 
predominant pushing border, in which we could not detect 
Figure 6: The percentage of RHAMM positive tumor cells increases from the primary tumor to the liver metastasis. 
FFPE blocks from seven matched primary tumors, lymph nodes and liver metastasis were sectioned and immunohistochemically stained 
for RHAMM. Whole tissue slides were scored. Box whiskers show minimum and maximum values. The bar indicates the median value. 
Representative RHAMM IHC stains are shown.
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any tumor buds in either group, and could therefore not 
measure a change in bud numbers or infiltration depth. 
Nevertheless, RHAMM silencing virtually abolished the 
ability of HCT116 and HT29 cells injected into the tail vein 
to form metastases. While the majority of mice injected 
with RHAMM+ cells developed multiple metastases in the 
liver, lung, kidney and lymph nodes, only a single mouse 
injected with RHAMM- cells developed a metastasis, and 
only in a single organ. This suggests that RHAMM is not 
only necessary for the dissemination of the primary tumor 
by contributing to proliferation, migration and invasion, 
but for some stage in the colonization of the secondary 
site as well. Our data are in line with previous reports 
describing a similar capacity of RHAMM to promote 
migration, extravasation and metastasis [22] formation in 
non-small cell lung carcinoma [24], melanoma [25] and 
pancreatic cancer [26].
Consistent with data obtained with cell lines, RNA-
Seq of primary tumors discordant for RHAMM revealed 
that its overexpression is associated with gene expression 
patterns characteristic for weaker cell-cell and cell-
substrate attachment, higher cell motility and increased 
proliferation. However, further studies are warranted to 
elucidate the molecular mechanisms underlying potential 
direct or indirect interactions between RHAMM and the 
identified genes.
Taken together, our findings show for the first time 
that RHAMM has a strong, direct effect on proliferation, 
migration and infiltration of CRC cell lines and tumors 
derived thereof, and suggest that this protein might serve 
as a possible target in CRC.
There are previous reports of targeting RHAMM 
in humans. In acute myeloid leukemia, myelodysplastic 
syndrome, and multiple myeloma, RHAMM activates 
cellular and humoral immune responses, and was thus 
chosen as a target for an anti-RHAMM peptide vaccination 
approach [27], which had some success in initial clinical 
trials. In these diseases, however, the specificity of the 
approach was an issue, as RHAMM was only weakly 
expressed on leukemic stem cells. Nevertheless, targeting 
RHAMM in CRC could prove more promising, as normal 
colonic mucosa is only sporadically and weakly positive 
for RHAMM. Therefore, a similar strategy might be fairly 
specific for tumor cells.
We propose that targeting RHAMM could 
specifically inhibit the growth and dissemination of CRC 
by targeting the main tumor body as well as tumor buds 
and micrometastatic initiator cells.
MATERIALS AND METHODS
Patient selection for next generation tissue 
microarray (ngTMA) construction
A well-characterized cohort of 335 non-consecutive, 
unselected colon cancer patients treated at the Inselspital 
in Bern, Switzerland between 2002 and 2011 was 
retrospectively included in this study. Clinical data 
were obtained from patient records including patient 
age at diagnosis, gender, tumor location and size, pre- 
and post-operative therapy, and overall survival time. 
An experienced GI pathologist (AL) reviewed all 
histomorphological data of the surgical resections. The 
clinicopathological features of all patients are listed in 
Supplementary Table 1. The median survival time was 
79 months (95% CI 68-114). The use of patient data has 
been approved by the local ethics committee, (Kantonale 
Ethikkomission Bern #KEK-BE 200/14).
ngTMA construction
The ngTMA was constructed as described before 
[29]. Ninety-four patients were excluded from the 
original cohort based on pre-operative treatment (n=51) 
or insufficient material (n=43) remaining on the tissue 
block. The ngTMA included two 0.6 mm tissue punches 
(cores) each from tumor center, tumor front, tumor 
stroma (including buds) and normal colorectal mucosa of 
241 patients. Additionally, each slide contained a set of 
punches derived from eight large, colorectal tumors with 
a homogenous histology, to serve as an inter-slide control 
for staining reproducibility.
Immunohistochemistry (IHC)
IHC was performed as described before [19, 28]. 
The specificity of the stain was confirmed by comparison 
with an alternate antibody (Novus EPR4055). This marker 
was used to confirm the previously reported relationship 
[19, 20] between the level of RHAMM expression in the 
tumor and overall survival, defined as the period of time 
in months from the date of diagnosis to the date of death.
Ki-67 (M7240, Dako) and cleaved Caspase 3 
(#9664, Cell signaling) IHC stains were performed on 
whole tissues sections analogously, with small alterations 
in the pretreatment (Citrate buffer, 30 minutes, at 95°C 
and 100°C, respectively), and incubation time (1 hours for 
both). The percentage of positive tumor cells was scored.
Evaluation of immunohistochemistry using 
digital image analysis
For the scoring of RHAMM staining on the 
ngTMA, RHAMM expression was calculated by using the 
percentage of tumor cells showing any marker positivity. 
An ngTMA spot was scored only when it contained more 
than 100 tumor cells. Normal mucosa served as an internal 
control, and RHAMM was evaluated as overexpressed 
in tumors when it exceeded the percentage of signal 
found in normal tissue (5%). The scoring was done both 
by eye by a postdoctoral fellow focusing on RHAMM 
(LS), an experienced gastrointestinal pathologist (HD), 
blinded to clinical data, and by a digital quantification 
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software (HALO, Indica Labs v1.94). HALO algorithm 
specifications: Image Zoom:0.25; Class List: Tumor; 
Classify Registered: Nuclear Stain:0.181,0.151,0.095; 
Positive Stain1: 0.164,0.286,0.433; Stain1 Localization: 
Cytoplasm; Minimum Tissue OD: 3.7e-002; Tissue 
Edge Thickness: 0.; Nuclear Contrast Threshold: 0.525; 
Minimum Nuclear OD: 9.5e-002; Minimum Nuclear Size: 
9.8; Maximum Nuclear Size: 571.7; Minimum Nuclear 
Roundness: 0.; Nuclear Segmentation Aggressiveness: 
0.385; Fill Nuclear Holes: 1; Maximum Cytoplasm 
Radius: 5.; Stain1 Min OD Weak: 7.6e-002; Stain1 Min 
OD Moderate: 0.123; Stain 1 Min OD Strong: 0.268.
The interobserver agreement of RHAMM 
immunohistochemistry scores was excellent between two 
observers (r=0.88) and between an observer and image 
analysis software (r= 0.8).
Tumor cell culture
Established human CRC cell lines HCT116, HCT15, 
DLD-1, HT29, SW480 and SW620 were purchased 
from European Collection of Cell Culture (ECACC) 
a year before the start of the project. HT29, LoVo and 
CACO 2 were either a kind gift or already present in the 
facilities. All cells were used within 10 passages from 
initial thawing. In addition, HT29 and HCT116 were 
authenticated by DNA fingerprinting prior to its use, 
and found to be a full match of the HT29 and HCT116 
reference profiles. HCT116, HCT15, DLD-1, LoVo and 
CACO-2 were maintained in RPMI 1640 supplemented 
with 10% fetal bovine serum (FBS), GlutaMAX-I, non-
essential amino acids (NEAA), 100 mM sodium pyruvate, 
10 mM HEPES (all from GIBCO). HT29 was maintained 
in McCoy’s 5A medium (Sigma) supplemented with 
10% FBS and GlutaMAX-I. SW480 and SW620 were 
cultured in L-15 Medium (Leibovitz) (Sigma-Aldrich) 
supplemented with 10% FBS and GlutaMAX-I. 
Kanamycin sulfate (GIBCO) was included with all media. 
Cells were cultured at 37°C with 5% CO2. Absence of 
mycoplasma contamination in cultured cells was verified 
by PCR testing prior to investigation.
Flow cytometry
The cell surface and intracellular expression of 
RHAMM in a panel of CRC cell lines was tested by flow 
cytometry using a RHAMM-specific monoclonal antibody 
(abcam clone 2D6, ab67003). To evaluate the intracellular 
expression, cells were fixed and permeabilized using the 
BD FACS™ Permeabilizing Solution 2 (#340973, BD 
Biosciences), following the manufacturer's protocol and 
then stained with anti-RHAMM antibody. Propidium 
iodide (PI, 0.5 μg/ml) was added to all samples prior to 
analysis to exclude dead cells. Samples were analyzed 
by a dual laser BD FACS Calibur flow cytometer (BD 
Biosciences), following exclusion of dead cells based on 
PI incorporation. Analysis was performed using FlowJo 
software (FlowJo LLC, Ashland, OR, USA).
Short hairpin RNA (shRNA) silencing
Five different bacterial cultures (MISSION® 
shRNA Bacterial Glycerol Stock Nr: TRCN0000061553; 
TRCN0000061555; TRCN0000333645; TRCN0000333646; 
TRCN0000333647, annotated 1-5) were purchased from 
Sigma-Aldrich, and were amplified for isolation of shRNA 
plasmid DNA. Self-inactivating replication incompetent 
viral particles were produced in packaging HEK293T cells 
by transfection of the purified plasmid. Target HT29 and 
HCT116 cells were infected with lentiviruses containing the 
different plasmids and selected for Puromycin resistance. 
Cells infected with a lentivirus carrying a scrambled shRNA 
sequence were used as a negative control. The efficiency 
of silencing was then tested by western blot and the cells 
transfected with the plasmid inducing the highest reduction 
in protein expression were selected and used for the 
functional experiments (Plasmid number 1 in Supplementary 
Figure 4).
Western blot analysis
Cells lysates were obtained by using 50 mM Tris 
pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS. Protein 
concentrations were determined by the Pierce BCA protein 
concentration assay according to the manufacturer’s 
instructions (Thermo Scientific, Waltham, MA, USA). 
Blots were probed with mouse anti-RHAMM (1:1000, 
clone 2D6, ab67003, abcam) and goat anti-β-actin 
(1:2000, Santa Cruz, Santa Cruz, CA, USA) antibodies. 
Secondary species-specific HRP-conjugated IgG 
(Santa Cruz) together with Pierce ECL (Thermo Fisher, 
Scientific Waltham, MA, USA) were used for detection 
of immunoreactive proteins. The cells with the highest 
reduction in protein expression were selected for further 
experiments.
Proliferation assay and cell cycle analysis
Three-thousand RHAMM silenced and control 
HT29 and HCT116 cells were seeded in a 96-well plate 
in the presence of 100 μg/ml low molecular weight 
HA (Sigma, 40583) and analyzed every 24 hours for 
6 days using the CYQUANT cell proliferation assay 
kit (Invitrogen, Carlsbad, CA, USA), according to the 
manufacturer’s protocol. Five well replicates were used 
per experiment.
To detect a change in cell cycle progression, 
RHAMM silenced and control HT29 and HCT116 cells 
were trypsinized, fixed with 1% paraformaldehyde for 15 
minutes and stored in 70% ethanol at -20°C for at least 
one hour. The cells were then centrifuged and stained 
with PI/RNase staining buffer (BD Biosciences) for 15 
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minutes, according to the manufacturer’s protocol. Upon 
staining the DNA content was analyzed by flow cytometry 
on a BD LSRFortessa instrument and the cell cycle 
profile was assessed by using FlowJo Software (FlowJo 
LLC, Ashland, Oregon). Five well replicates were used 
per experiment. Three different experiments with two 
technical replicates were performed.
Migration and invasion assay
HT29 and HCT116 tumor cells were suspended in 
serum-free medium, and seeded in the upper chambers 
of transwell plates onto uncoated or Matrigel-coated 
membranes (8 μm pore size, Corning). After 20 hours, the 
number of cells that had migrated into the lower chambers 
was quantified by CyQUANT Cell Proliferation Assay Kit 
(Invitrogen, Carlsbad, CA, USA). The migration capacity 
was indicated with the relative fluorescent units (RFU) of 
cells migrated through the membrane and the invasiveness 
was calculated according to the following formula: (mean 
of relative fluorescent units (RFU) of cells invaded 
through Matrigel-coated membranes / mean RFU of cells 
migrated through un-coated membranes).
Analysis of tumorigenic and metastatic potential 
in vivo
In vivo experiments were approved by the Cantonal 
Veterinary Office Basel-Stadt, license number 2266. 
Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,) mice 
from Charles River Laboratories (Sulzfeld, Germany), 
were bred and maintained under specific pathogen-
free conditions in the animal facility of the Department 
of Biomedicine, University of Basel. To assess the 
tumorigenicity, 1×105 HT29 or HCT116 cells, infected 
with lentiviral particles carrying either a RHAMM 
shRNA or a scrambled control, were suspended in a 1:1 
PBS and Matrigel (BD Biosciences) dilution and injected 
subcutaneously in the flank of 8 week old NSG mice. 
Each group consisted of 4 animals. Tumor formation 
was monitored twice weekly by palpation and caliper 
measurements. Mice were sacrificed when the tumors 
reached a maximum size of 10 mm. Tumor volumes (in 
mm3) were determined according to the formula (length 
x width2/2).
To examine metastasis formation of RHAMM 
silenced versus wild type HT29 or HCT116 cells, 105 cells 
were resuspended in 100 μl PBS and injected into the tail 
vein of NSG mice. After 4 weeks, metastasis formation in 
organs of interest (lungs, livers, kidney, and lymph nodes) 
was assessed and confirmed by histological evaluation on 
hematoxylin and eosin stains. The slides were scanned 
with the Pannoramic slide scanner (3DHISTECH) at 20x. 
The peripheral blood of the mice was taken immediately 
after the sacrifice in order to evaluate the presence of 
circulating tumor cells (CTCs) in the blood. CTCs were 
detected by staining with an anti-human EpCAM antibody 
(BD Biosciences, Switzerland; clone EBA-1; #347200) 
on the BD Calibur cytometer. The number of CTCs was 
normalized to the volume of blood taken.
Patient selection for RNA-Seq
Six stage 2 primary tumors with either low RHAMM 
levels or RHAMM overexpression were selected from 
56 random, non-consecutive CRC cases treated by 
surgery between 2010 and 2013 at the Bern University 
Hospital, based on RHAMM protein detection by IHC 
and availability of fresh material at the Tumor Bank 
Bern. Information on patient gender, age at diagnosis, pT 
(primary tumor), pN (regional lymph node metastasis), as 
well as presence and location of distant metastasis was 
extracted from patient files in accordance with the UICC 
TNM classification 7th edition. Patient characteristics 
are provided in Supplementary Table 2. For RNA-Seq 
analysis, full tissue sections were cut from each tumor 
set and tumor tissue was scratched under visual control 
to minimize contamination by non-neoplastic tissue. RNA 
was isolated from 15 mg tissue using the Absolutely RNA 
Miniprep Kit (Ambion, 400800).
RNA-Seq data analysis
Between 30 and 45 million read pairs (2×100 bp) 
were obtained per sample and the quality of the reads was 
assessed using fastqc v.0.10.1 (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). The reads were mapped 
to the human reference genome (ensembl, GRCh37.75) 
with Tophat v.2.0.13 [29]. We used htseq-count v.0.6.1 
[30] to count the number of reads overlapping with each 
gene, as specified in the ensembl annotation (release 
75). The Bioconductor package DESeq2 v. 1.6.3 [31] 
was used to test for differential gene expression between 
conditions. In total, we performed four different pairwise 
comparisons, two between expression levels within tumor 
types and two between tumor types within expression 
levels. The P-values were adjusted for multiple testing 
using the false discovery rate approach of Benjamini-
Hochberg as implemented in DESeq2. SetRank [32] 
was used to identify gene sets enriched for differentially 
expressed genes. The tool collects gene sets from eight 
different databases (GO, ENCODE, Pathway Interaction 
Database, Reactome, BioCyc, KEGG, PhosphoSitePlus 
and WikiPathways), and performs an enrichment analysis 
that accounts for overlap between gene sets.
Statistical analysis
For survival assessment using non-dichotomized 
data, Cox regression analyses were performed. Hazard 
ratios (HR) and 95% confidence intervals (CI) were used 
to determine the effect size. Differences in survival time 
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were displayed using dichotomized data and standard 
Kaplan-Meier curves and tested using the log-rank test 
in univariate analysis. The time of survival was defined 
as the time of an event occurrence (death) or censored 
(patient lost to follow-up) relative to the date of operation.
For the functional in vitro and in vivo assays, 
statistical analyses were performed using 2-tailed Student’s 
T-test, one-way ANOVA, or the Mann-Whitney-U test as 
appropriate. Analyses were performed using SPSS Version 
23 (IBM Corporation). P-values ≤0.05 were considered 
significant.
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